Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2024-03-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Regulatory Filings
2024-03-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th Board of Directors' 4th meeting of Qidi Pharmaceutical Group Co., Ltd. It includes approvals of the 2023 Annual Report, Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Evaluation Report, and other governance and financial matters. The document references the full 2023 Annual Report and other reports being published elsewhere (on cninfo.com.cn and newspapers), indicating this document itself is not the full annual report but a board meeting resolution announcement. It also includes voting results and decisions on governance and financial issues. The document length is under 5,000 characters and primarily serves as a formal announcement of board meeting decisions rather than the full report or financial statements. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management decisions.
2024-03-27 Chinese
中德证券有限责任公司关于启迪药业集团股份公司2023年度募集资金存放与使用的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by Zhongde Securities regarding the 2023 annual use and storage of raised funds by Qidi Pharmaceutical Group Co., Ltd. It details the amount of funds raised, their usage over multiple years, the management and storage of these funds, regulatory compliance, and audit opinions. The document includes detailed financial figures and compliance with regulatory guidelines related to the management of raised funds. It is a specialized audit and verification report focusing on the use and management of fundraising proceeds, not a full annual report or earnings release. It is not a simple announcement or certification but contains substantive financial and compliance information. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific regulatory or compliance matters, excluding full annual reports. FY 2023
2024-03-27 Chinese
敏感信息排查制度（2024年3月修订）
Governance Information Classification · 95% confidence The document is titled '敏感信息排查制度' (Sensitive Information Screening System) and details internal procedures and policies for managing sensitive information disclosure within the company. It references regulatory frameworks such as the Shenzhen Stock Exchange Listing Rules and internal company governance documents. The content focuses on internal controls, reporting obligations, and confidentiality measures related to sensitive information and insider trading prevention. There are no financial statements, earnings data, or shareholder meeting materials. The document is a governance or compliance policy rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is about 5,073 characters, which is sufficient for a detailed policy document rather than a brief announcement.
2024-03-27 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2024-03-27 Chinese
2023年度独立董事述职报告（雷振华）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2023" from a specific independent director of the company. It details the director's background, attendance at board and committee meetings, exercise of duties, communication with auditors and investors, and oversight of company governance and financial reporting. It is a detailed narrative report on the director's activities and observations during the year, rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. The content aligns with a management or governance-related report focusing on board activities and oversight. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it relates to board member activities and governance reporting.
2024-03-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.